[1]

齐今吾. 内分泌疾病相关高血糖和(或)糖尿病// 刘新民, 齐今吾, 杨晓凤, 等. 内分泌疾病: 鉴别诊断与治疗学. 北京: 人民军医出版社, 2009: 358.
[2] Bhattacharyya A, Wiles PG. Diabetic ketocidosis precipitated by thyrotoxicosis. Postgrad Med J, 1999, 75(833): 291-292.
[3] Moller N, Nielsen S, Nyholm B, et al. Glucose turnover, fuel oxida-tion and forearm substrate exchange in patients with thyrotoxicosis before and after medical treatment. Clin Endocrinol (Oxf), 1996, 44(4): 453-459.  doi: 10.1046/j.1365-2265.1996.692514.x
[4]

Loeb JN. Metabolic changes in thyrotoxicosis//Braverman LE, Utiger RD. Werner and Ingbar's the thyroid. Philadelphi a: Lippincott-Raven, 1996: 687-693.
[5] Gasińska T, Nowak S, Beldzik A, et al. Levels of free fatty acids in plasma, tissue utilization coefficient of glucose K and insulin secre-tion following intravenous glucose load in hyper-thyroid patients treated with propranolol or acebutolol. Pol Tyg Lek, 1994, 49 (1-3): 7-10.
[6] Mokuno T, Uchimura K, Hayashi R, et al. Glucose transporter 2 concentrations in hyper-and hypothyroid rat livers. J Endocrinol, 1999, 160(2): 285-289.  doi: 10.1677/joe.0.1600285
[7] Bech K, Damsbo P, Eldrup E, et al. Beta-cell function and glucose and lipidoxidation in Graves′ disease. Clin Endocrinol(oxf), 1996, 44(1): 59-66.  doi: 10.1046/j.1365-2265.1996.636458.x
[8] Yki-Järvinen H. Toxicity of hyperglycaemia in type 2 diabetes. Diabetes Metab Rev, 1998, 14 (Suppl 1): S45-S50.
[9] Stumvoll M, Fritsche A, Stefan N, et al. Evidence against a ratelimiting role of proinsulin processing for maximal insulin secretion in subjects with impaired glucose tolerance and beta-cell dysfunction. J Clin Endocrinol Metab, 2001, 86(3): 1235-1239.
[10] Røder ME, Schwartz RS, Prigeon RL, et al. Reduced pancreatic B cell compensation to the insulin resistance of aging: impact on proinsulin and insulin levels. J Clin Endocrinol Metab, 2000, 85(6): 2275-2280.
[11] Larsson H, Ahrén B. Relative hyperproinsulinemia as a sign of islet dysfunction in women with impaired glucose tolerance. J Clin Endocrinol Metab, 1999, 84(6): 2068-2074.
[12] Eizirik DL, Darville MI. Beta-cell apoptosis and defense mecha-nisms: lessons from type 1 diabetes. Diabetes, 2001, 50(Suppl 1): S64-S69.
[13] Jörns A, Tiedge M, Lenzen S. Thyroxine induces pancreatic beta cell apoptosis in rats. Diabetologia, 2002, 45(6): 851-855.  doi: 10.1007/s00125-002-0842-5
[14] Yavuz DG, Yüksel M, Deyneli O, et al. Association of serum paraoxonase activity with insulin sensitivity and oxidative stress in hyperthyroid and TSH-suppressed nodular goiter patients. Clin Endocrinol, 2004, 61(4): 515-521.  doi: 10.1111/j.1365-2265.2004.02123.x
[15] Riis AL, Gravholt CH, Djurhuns CB, et al. Elevated regional lipolysis in hyperthyroidism. J Clin Endocrinol Matab, 2002, 87(10): 4747-4753.  doi: 10.1210/jc.2002-020174
[16] Dimitriadis G, Mitrou P, Lambadiari V, et al. Glucose and lipid fluxes in the adipose tissue after meal ingestion in hyperthyroidism. J Clin Endocrin Metab, 2006, 91(3): 1112-1118.  doi: 10.1210/jc.2005-0960
[17] Shimabukuro M, Zhou YT, Levi M, et al. Fatty acid induced beta-cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci USA, 1998, 95(5): 2498-2502.  doi: 10.1073/pnas.95.5.2498
[18] Heimberg H, Heremans Y, Jobin C, et al. Inhibition of cytokine induced NF-kappa B activation by adenovirus mediated expression of a NF-kappaB super-repressor prevent beta-cell apoptosis. Diabetes, 2001, 50(10): 2219-2224.  doi: 10.2337/diabetes.50.10.2219
[19] Iossa S, Lionetti L, Mollica MP, et al. Fat balance and serum leptin concentrations in normal, hypothyroid, and hyperthyroid rats. Int J Obes Relat Metab Disord, 2001, 25(3): 417-425.  doi: 10.1038/sj.ijo.0801516
[20] Roubsanthisuk W, Watanakejorn P, Tunlakit M, et al. Hyperthy-roidism induces glucose intolerance by lowering both insulin secretion and peripheral insulin sensitivity. J Med Assoc Thai, 2006, 89(Suppl 5): S133-S140.
[21] Jenkins RC, Valcavi R, Zini M, et al. Association of elevated insulin-like growth factor binding protein-1 with insulin resistance in hyperthyroidism. Clin Endocrinol (Oxf), 2000, 52(2): 187-195.  doi: 10.1046/j.1365-2265.2000.00924.x
[22] Fukuchi M, Shimabukuro M, Shimajiri Y, et al. Evidence for a deficient pancreatic beta-cell response in a rat model of hyperthy-roidism. Life Sci, 2002, 71(9): 1059-1070.  doi: 10.1016/S0024-3205(02)01791-5
[23] Douglas RS, Gianoukakis AG, Kamat S, et al. Aberrant expression of the insulin-like crowth factor-1 receptor by T cells from patients with Graves' disease may carry functional consequences for disease pathogenesis. J Immunol, 2007, 178(5): 3281-3287.  doi: 10.4049/jimmunol.178.5.3281
[24] Douglas RS, Naik V, Hwang CJ, et al. B cells from patients with Graves'disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis. J Immunol, 2008, 181(8): 5768-5774.  doi: 10.4049/jimmunol.181.8.5768
[25] Maugendre D, Sonnet E, Derrien C, et al. Combined analysis of long-term anti-beta-cell humoral reactivity in type 1 diabetes with and without thyroid disease. Diabetes Metab, 1999, 25(1): 28-33.
[26] Wu TJ, Huang SM, Taylor RL, et al. Abnormal proinsulin levels in thyroid dysfunction measured by a sensitive proinsulin immuno-chemiluminoassay. Ann Clin Lab Sci, 1998, 28(2): 82-87.
[27] Hwang IK, Kim IY, Kim YN, et al. Effects of methimazole on the onset of type 2 diabetes in leptin receptor-deficient rats. J Vet Med Sci, 2009, 71(3): 275-280.  doi: 10.1292/jvms.71.275
[28] 闫瑞红, 杨天正, 周振虎, 等. 131I治疗Graves病合并糖尿病的疗效分析. 中华核医学杂志, 2008, 28(5): 351.
[29] 赵德善, 孔繁振, 司宏伟, 等. 儿童和青少年甲状腺功能亢进症的131I治疗. 中华内分泌代谢杂志, 2006, 22(6): 566-568.  doi: 10.3760/j.issn:1000-6699.2006.06.017
[30]

廖二元, 超楚生. 内分泌学// 戴如春, 廖二元. 继发性糖尿病与遗传性糖尿病. 北京: 人民卫生出版社, 2003: 1620.